Navigation Links
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors. KOS-1584/R1645 showed activity in 32% of patients (13 of 41 evaluable) including activity in patients with non-small cell lung, ovarian, breast, prostate, head and neck and other cancers. Common toxicities were generally low-grade and manageable. Data from this ongoing trial were presented on Sunday, June 3, 2007, in a poster titled, "Phase 1 Trial of KOS-1584 (a Novel Epothilone) Using Two Weekly Dosing Schedules," by Howard Burris, M.D., Sarah Cannon Research Institute, Nashville, TN, at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Epothilones are promising anticancer agents due to their taxane-like mechanism of action and demonstrated activity in taxane resistant tumors," said Dr. Burris. "Kosan's novel epothilone is of particular interest due to its level of antitumor activity in patients with highly refractory disease and manageable side effect profile. This promising compound warrants continued development."

"KOS-1584/R1645 is a highly potent compound with attractive pharmaceutical properties, including a long half-life, large volume of distribution, wide therapeutic index and ease of formulation that has demonstrated encouraging activity in Phase 1 trials," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We believe that KOS-1584/R1645, based on our novel epothilone D backbone, has the potential to be superior to other epothilones currently in development and ultimately emerge as a meaningful competitor in the taxane market. We look forward to initiating a robust Phase 2 clinical program, with the support of our partner Roch
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

Post Your Comments:
(Date:11/24/2009)...ov.24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgian...oaccident,wasactuallyfullyconsciousandawakeduringt...t.TheDynaVoxEyeMaxwasfeaturedinthesegmenttoillustr...scanunlockcommunication. ,, WHEN:GoodMorningAme....dynavoxtech.com ,, WHO:RomHoubenswasanengi...
(Date:11/24/2009)....24/PRNewswire-FirstCall/--AnadysPharmaceuticals,I...tthe21stAnnualPiperJaffrayHealthcareConferenceonTu...conferenceisbeingheldatTheNewYorkPalaceHotel.Steve...nadys,willprovideanoverviewofAnadysanditsclinicald...ratepresentationwillbesimultaneouslywebcastandcanb...
(Date:11/24/2009)....24/PRNewswire/--Accumetrics,Inc.,aprivately-heldd...irstrapidandeasy-to-usediagnosticsystemformeasurin...s(e.g.Plavix®andaspirin),announcedtodaythatTi...ryJ.Tibbitts,ChiefFinancialOfficerofAccumetrics,wi...erJaffrayHealthCareConferencebeingheldinNewYorkCit...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Dr Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show 13558 1Dr Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show 13558 2Dr Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show 13558 3IRIDEX Reports Second Quarter 2009 Financial Results 54491 1IRIDEX Reports Second Quarter 2009 Financial Results 54491 2IRIDEX Reports Second Quarter 2009 Financial Results 54491 3IRIDEX Reports Second Quarter 2009 Financial Results 54491 4IRIDEX Reports Second Quarter 2009 Financial Results 54491 5IRIDEX Reports Second Quarter 2009 Financial Results 54491 6Martek Signs Sole Source ARA Supply Agreement with Puleva Food S L 13557 1Martek Signs Sole Source ARA Supply Agreement with Puleva Food S L 13557 2Martek Signs Sole Source ARA Supply Agreement with Puleva Food S L 13557 3
...- Gentium S.p.A. (Nasdaq:,GENT) announced the pres...t support the safety, activity, synergy and potent...ion with anticancer,therapy in multiple myeloma. I...pany,s ongoing Phase I/II clinical trial for patie...ith Defibrotide in,combination with chemotherapy, ...
... - Cytochroma Inc.,announced today positive data f...The initial top-line results from this trial,showe...e study,results are expected in August 2007. , The...l,placebo-controlled, randomized study of CTA018 ...n this trial, the safety of,CTA018 Injection was e...
Other Medicine Technology:Gentium's Defibrotide Seen as Active in Multiple Myeloma 2Gentium's Defibrotide Seen as Active in Multiple Myeloma 3Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3
(Date:11/25/2009)...sks placed under the skin kill tumor cells, study ...News) -- A cancer vaccine delivered in a fingernai... a new study reports. , The method uses polymer...ed with tumor-specific antigens and implanted unde...k tumors. The Harvard University scientists who de...
(Date:11/25/2009)...HINGTON,Nov.25/PRNewswire-FirstCall/--TheAdvisoryB...participateinthe21stAnnualPiperJaffrayHealthCareCo...cember2,2009at3:00PM(EST),willbetheCompany,sChiefE...sChiefFinancialOfficer,MichaelT.Kirshbaum.Theprese...te,foundat http://www.advisoryboardcompany.com ,th...
(Date:11/25/2009)...NTURA,Fla.,Nov.25/PRNewswire/--DanielTouizer,CEOof...ranteedissuehealthinsurancebenefitprograms,isconce...bermeansnearlyoneinfiveAmericansarewithoutafull-ti...unemploymentratesaredeterminedbytheU-6number,which... Dani e l T ouizer ."Thesestatisticsarealarm...
(Date:11/25/2009)...ES (Nov. 25, 2009) Melvin R. Kaplan, MD, FACP, a ...research institute that became Los Angeles Biomedi...er (LA BioMed), will be honored by the American Co...he care of patients. , At its April 22, 2010 mee...s will present Dr. Kaplan with the Ralph O. Claypo...
(Date:11/25/2009)...hemo boosts surgery success for patients with live...Y, Nov. 25 (HealthDay News) -- Adding the drug cet...rs and boost the odds of successful surgery in col... liver lesions, new research suggests. , , Tum... half of patients with colorectal cancer. Most com...
Breaking Medicine News(10 mins):Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:1 of LA BioMed's founders to be honored 2Health News:Cetuximab Helps Treat Colorectal Cancer 2
...step forward in the field of AIDS was disclosed by...ording to this 2-5AN6B, a nucleic acid, could actu...rus from replicating. This work was led by Rob...d for AIDS treatment will be effective in treating...
...ersing brain impairment that strikes in the early ...been identified by scientists.// The findings...n form of BSE, if it can be detected before it has... infected. But many scientists believe that thousa...
... a U.S based company promises a test that will s...sts.// The company has come out with a proced...atal test that searches for chromosomal abnormalit...he market there is no test available that can reli...
...nment has refused to grant product patent for Gliv...arma giant. As a result Novartis may not be able t...gapore and China are the countries where Novartis ...sion by the Indian government could hamper the lau...
...ts of Pinewood elementary in Prince George, Canada...ken strips were served to them as part of the scho...a case of food poisoning was registered only after... immediately notified the Northern Health authorit...
...e mouth heal more slowly in women and older adults...cago reveals.// "While wounds to the skin heal...ested the opposite is true for healing of wounds i...uth wounds heal faster than women's." Older wo...
Other Medicine News:Health News:Researchers Make Strides in VCJD Detection 2Health News:Simple Blood Test may Replace Invasive Prenatal Tests 2Health News:Oral Wounds Heal Slower in Women, Older Adults 2
... Deeper Lesions ,Designed for the treatment ...Freezor MAX is a powerful ablation-only catheter. ...s designed to provide maximum cryo performance. It... cryocatheters, but its larger shaft and ablation ...
...is GEs premier digital cardiovascular system that ...raphy, and a new dimension of comfort and diagnost...tomer input, using Six Sigma practices, GE has cre...ar system that delivers what customers want: Bette...
...onitors and controls patient temperature primarily...ssociated with surgery, trauma, or other medical c... feedback provided from a patient temperature prob...bient (room air) and 42C (107.6F) to achieve a pre...
...onic Stethoscope Model 4100WS features amplificati...echnology allowing you to reduce ambient noise by ...ical body sounds. Three frequency modes are availa...ounds: Bell (20-200 Hz), Diaphragm (100-500 Hz), a...
Medicine Products: